(Sharecast News) - Hutchmed announced on Monday that China's National Medical Products Administration (NMPA) has approved the new drug application for the combination of 'Orpathys'. Or savolitinib, and 'Tagrisso', or osimertinib, to treat patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC) with MET amplification following...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE